simvastatin (35.4%), atorvastatin (27.6%) and pravastatin (13.2%) were the most prescribed initial drugs. A total of 503,023 patients were considered for the adherence analysis: 34.9% of subjects had MPR < 0.4; 34.7% between 0.4 and 0.8; and 30.4% > 0.8. CONCLUSION: Persistent and adherence with hypolipemic medications is far from optimal in this large cohort of subjects. This phenomenon is common to many asymptomatic chronic therapies and deserves further investigations, as it indicates that a relevant part of drug resources are spent without a predictable clinical benefit. The study evaluates adherence with antihypertensive drug treatments in newly treated patients, outlines characteristics of patients discontinuing treatment (discontinuation risk profiling), and calculates amount of resources allocated on not effective treatment patterns (eg, discontinuation). An administrative database kept by the Local Health Unit of Pavia listing patient baseline characteristics, drug prescriptions and hospital admissions was used to perform a population-based retrospective analysis. METHODS: The study included all newly treated users of antihypertensive drugs, Ն18 years of age, receiving a first prescription for diuretics, beta-blockers, calcium channelblockers, ACE inhibitors, angiotensin II antagonists or other antihypertensive drugs between January 1st, 2001 and December 31st, 2003. Patients were observed for 365 days. Adherent patients were defined as having a duration of therapy >273 days and DDD-standardized mean daily dose Ն0.8. RESULTS: A total of 42,000 patients were included in the study.Excluding ACE inhibitors (34.3%) other antihipertensive classes were included in a range from 13.3% up to 18.8%. The 75.1% of patients was not adherent to antihypertensive treatment. Those prescribed with angiotensin II antagonists were more likely to adhere treatment than those started on other antihypertensive classes. Poor adherence was associated with younger age, lower prevalence of concurrent chronic pharmacotherapies and lower prevalence of previous hospitalizations for cardiovascular diseases. The overall cost amounted to € 5.320 mio € of which 36.4% was accounted for not adherent patients. CONCLU-SION: The clinical, social, and economic importance of treating hypertension requires the analysis and the implementation of tools for monitoring antihypertensive drug utilization as to assess the extent to which results from clinical research are brought into clinical practice. Administrative databases offer a powerful and low cost tool, providing detailed and useful, population-wide epidemiological and economic information for antihypertensive drug utilization. Abstracts A431
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